Peptimmune, Inc. Garners $8,200,000 Series D Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e0e7bbed-5567-43e6-875f-7113717fdfe4&Preview=1
Date
1/17/2008
Company Name
Peptimmune, Inc.
Mailing Address
64 Sidney Street Cambridge, MA 02139
Company Description
Peptimmune is a clinical stage biotechnology company that is utilizing both novel and proven technologies to improve the therapeutic management of chronic autoimmune and metabolic disorders.
Website
http://www.peptimmune.com
Transaction Type
Venture Equity
Transaction Amount
$8,200,000
Transaction Round
Series D
Proceeds Purposes
Proceeds of the $8.2 million second tranche are expected to be used mainly to advance clinical development of Peptimmune’s multiple sclerosis treatment, PI-2301. More than 400,000 Americans have multiple sclerosis (MS), and worldwide MS may affect over 2.5 million individuals, according to the company.
M&A Terms
Venture Investor
New Enterprise Associates
Venture Investor
MPM Capital
Venture Investor
Hunt Ventures
Venture Investor
Silicon Valley Bank